肝性脳症治療のグローバル市場予測2023-2029

◆英語タイトル:Global Hepatic Encephalopathy Treatment Market Growth 2023-2029

LP Informationが発行した調査報告書(LP23OT8948)◆商品コード:LP23OT8948
◆発行会社(リサーチ会社):LP Information
◆発行日:2023年10月
◆ページ数:100
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野:医薬品&ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥556,320見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥834,480見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,112,640見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

LP Informationの最新刊調査レポート「肝性脳症治療のグローバル市場」は、過去の販売実績から2022年の世界の肝性脳症治療の総販売量を検討し、2023年から2029年の予測される肝性脳症治療の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の肝性脳症治療の市場規模を掲載し、XXX百万米ドル規模の世界の肝性脳症治療市場の詳細な分析を提供します。本インサイトレポートは、世界の肝性脳症治療業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の肝性脳症治療市場における各社の独自のポジションをより深く理解するために、肝性脳症治療製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の肝性脳症治療市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。肝性脳症治療の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000%と予測されています。肝性脳症治療の中国市場は、2023年から2029年までの年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。肝性脳症治療のヨーロッパ市場は、2023年から2029年にかけて年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

肝性脳症治療の世界主要メーカーとしては、Mallinckrodt Pharmaceuticals、 Salix Pharmaceuticals、 GlaxoSmithKline plc.、 Pfizer Inc.、 ASKA Pharmaceutical Co., Ltd.、 Bausch Health、 Johnson & Johnson Services, Inc.、 Janssen Global Services、 Takeda Pharmaceutical Company Limited、 Merck & Co., Inc.などを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000%のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の肝性脳症治療市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場セグメンテーション】

この調査では肝性脳症治療市場をセグメンテーションし、種類別 (経口式、注射式)、用途別 (病院薬局、小売薬局、オンライン薬局)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分:経口式、注射式

・用途別区分:病院薬局、小売薬局、オンライン薬局

・地域別区分
南北アメリカ(米国、カナダ、メキシコ、ブラジル)
アジア太平洋(中国、日本、韓国、東南アジア、インド、オーストラリア)
ヨーロッパ(ドイツ、フランス、イギリス、イタリア、ロシア)
中東・アフリカ(エジプト、南アフリカ、イスラエル、トルコ、GCC諸国)

【本レポートで扱う主な質問】

・世界の肝性脳症治療市場の10年間の市場状況・展望は?
・世界および地域別に見た肝性脳症治療市場成長の要因は何か?
・肝性脳症治療の市場機会はエンドマーケットの規模によってどのように変化するのか?
・肝性脳症治療のタイプ別、用途別の内訳は?
・新型コロナウイルスとロシア・ウクライナ戦争の影響は?

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要:肝性脳症治療の年間販売量2018-2029、地域別現状・将来分析
・肝性脳症治療の種類別セグメント:経口式、注射式
・肝性脳症治療の種類別販売量:2018-2023年の販売量、売上、市場シェア、販売価格
・肝性脳症治療の用途別セグメント:病院薬局、小売薬局、オンライン薬局
・肝性脳症治療の用途別販売量:2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の肝性脳症治療市場
・企業別のグローバル肝性脳症治療市場データ:2018-2023年の年間販売量、市場シェア
・企業別の肝性脳症治療の年間売上:2018-2023年の売上、市場シェア
・企業別の肝性脳症治療販売価格
・主要企業の肝性脳症治療生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

肝性脳症治療の地域別レビュー
・地域別の肝性脳症治療市場規模2018-2023:年間販売量、売上
・主要国別の肝性脳症治療市場規模2018-2023:年間販売量、売上
・南北アメリカの肝性脳症治療販売の成長
・アジア太平洋の肝性脳症治療販売の成長
・ヨーロッパの肝性脳症治療販売の成長
・中東・アフリカの肝性脳症治療販売の成長

南北アメリカ市場
・南北アメリカの国別の肝性脳症治療販売量、売上(2018-2023)
・南北アメリカの肝性脳症治療の種類別販売量
・南北アメリカの肝性脳症治療の用途別販売量
・米国市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の肝性脳症治療販売量、売上(2018-2023)
・アジア太平洋の肝性脳症治療の種類別販売量
・アジア太平洋の肝性脳症治療の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の肝性脳症治療販売量、売上(2018-2023)
・ヨーロッパの肝性脳症治療の種類別販売量
・ヨーロッパの肝性脳症治療の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の肝性脳症治療販売量、売上(2018-2023)
・中東・アフリカの肝性脳症治療の種類別販売量
・中東・アフリカの肝性脳症治療の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・肝性脳症治療の製造コスト構造分析
・肝性脳症治療の製造プロセス分析
・肝性脳症治療の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル:直接販売チャンネル、間接販売チャンネル
・肝性脳症治療の主要なグローバル販売業者
・肝性脳症治療の主要なグローバル顧客

地域別の肝性脳症治療市場予測レビュー
・地域別の肝性脳症治療市場規模予測(2024-2029)
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・肝性脳症治療の種類別市場規模予測
・肝性脳症治療の用途別市場規模予測

主要企業分析
Mallinckrodt Pharmaceuticals、 Salix Pharmaceuticals、 GlaxoSmithKline plc.、 Pfizer Inc.、 ASKA Pharmaceutical Co., Ltd.、 Bausch Health、 Johnson & Johnson Services, Inc.、 Janssen Global Services、 Takeda Pharmaceutical Company Limited、 Merck & Co., Inc.
・企業情報
・肝性脳症治療製品
・肝性脳症治療販売量、売上、価格、粗利益(2018-2023)
・主要ビジネス概要
・最新動向

調査結果および結論

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hepatic Encephalopathy Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Hepatic Encephalopathy Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Hepatic Encephalopathy Treatment by Country/Region, 2018, 2022 & 2029
2.2 Hepatic Encephalopathy Treatment Segment by Route
2.2.1 Oral
2.2.2 Injectable
2.3 Hepatic Encephalopathy Treatment Sales by Route
2.3.1 Global Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
2.3.2 Global Hepatic Encephalopathy Treatment Revenue and Market Share by Route (2018-2023)
2.3.3 Global Hepatic Encephalopathy Treatment Sale Price by Route (2018-2023)
2.4 Hepatic Encephalopathy Treatment Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.5 Hepatic Encephalopathy Treatment Sales by Application
2.5.1 Global Hepatic Encephalopathy Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Hepatic Encephalopathy Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Hepatic Encephalopathy Treatment Sale Price by Application (2018-2023)
3 Global Hepatic Encephalopathy Treatment by Company
3.1 Global Hepatic Encephalopathy Treatment Breakdown Data by Company
3.1.1 Global Hepatic Encephalopathy Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Hepatic Encephalopathy Treatment Sales Market Share by Company (2018-2023)
3.2 Global Hepatic Encephalopathy Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Hepatic Encephalopathy Treatment Revenue by Company (2018-2023)
3.2.2 Global Hepatic Encephalopathy Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Hepatic Encephalopathy Treatment Sale Price by Company
3.4 Key Manufacturers Hepatic Encephalopathy Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hepatic Encephalopathy Treatment Product Location Distribution
3.4.2 Players Hepatic Encephalopathy Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Hepatic Encephalopathy Treatment by Geographic Region
4.1 World Historic Hepatic Encephalopathy Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Hepatic Encephalopathy Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Hepatic Encephalopathy Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Hepatic Encephalopathy Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Hepatic Encephalopathy Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Hepatic Encephalopathy Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Hepatic Encephalopathy Treatment Sales Growth
4.4 APAC Hepatic Encephalopathy Treatment Sales Growth
4.5 Europe Hepatic Encephalopathy Treatment Sales Growth
4.6 Middle East & Africa Hepatic Encephalopathy Treatment Sales Growth
5 Americas
5.1 Americas Hepatic Encephalopathy Treatment Sales by Country
5.1.1 Americas Hepatic Encephalopathy Treatment Sales by Country (2018-2023)
5.1.2 Americas Hepatic Encephalopathy Treatment Revenue by Country (2018-2023)
5.2 Americas Hepatic Encephalopathy Treatment Sales by Route
5.3 Americas Hepatic Encephalopathy Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hepatic Encephalopathy Treatment Sales by Region
6.1.1 APAC Hepatic Encephalopathy Treatment Sales by Region (2018-2023)
6.1.2 APAC Hepatic Encephalopathy Treatment Revenue by Region (2018-2023)
6.2 APAC Hepatic Encephalopathy Treatment Sales by Route
6.3 APAC Hepatic Encephalopathy Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Hepatic Encephalopathy Treatment by Country
7.1.1 Europe Hepatic Encephalopathy Treatment Sales by Country (2018-2023)
7.1.2 Europe Hepatic Encephalopathy Treatment Revenue by Country (2018-2023)
7.2 Europe Hepatic Encephalopathy Treatment Sales by Route
7.3 Europe Hepatic Encephalopathy Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hepatic Encephalopathy Treatment by Country
8.1.1 Middle East & Africa Hepatic Encephalopathy Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Hepatic Encephalopathy Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Hepatic Encephalopathy Treatment Sales by Route
8.3 Middle East & Africa Hepatic Encephalopathy Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hepatic Encephalopathy Treatment
10.3 Manufacturing Process Analysis of Hepatic Encephalopathy Treatment
10.4 Industry Chain Structure of Hepatic Encephalopathy Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hepatic Encephalopathy Treatment Distributors
11.3 Hepatic Encephalopathy Treatment Customer
12 World Forecast Review for Hepatic Encephalopathy Treatment by Geographic Region
12.1 Global Hepatic Encephalopathy Treatment Market Size Forecast by Region
12.1.1 Global Hepatic Encephalopathy Treatment Forecast by Region (2024-2029)
12.1.2 Global Hepatic Encephalopathy Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Hepatic Encephalopathy Treatment Forecast by Route
12.7 Global Hepatic Encephalopathy Treatment Forecast by Application
13 Key Players Analysis
13.1 Mallinckrodt Pharmaceuticals
13.1.1 Mallinckrodt Pharmaceuticals Company Information
13.1.2 Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.1.3 Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Mallinckrodt Pharmaceuticals Main Business Overview
13.1.5 Mallinckrodt Pharmaceuticals Latest Developments
13.2 Salix Pharmaceuticals
13.2.1 Salix Pharmaceuticals Company Information
13.2.2 Salix Pharmaceuticals Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.2.3 Salix Pharmaceuticals Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Salix Pharmaceuticals Main Business Overview
13.2.5 Salix Pharmaceuticals Latest Developments
13.3 GlaxoSmithKline plc.
13.3.1 GlaxoSmithKline plc. Company Information
13.3.2 GlaxoSmithKline plc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.3.3 GlaxoSmithKline plc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GlaxoSmithKline plc. Main Business Overview
13.3.5 GlaxoSmithKline plc. Latest Developments
13.4 Pfizer Inc.
13.4.1 Pfizer Inc. Company Information
13.4.2 Pfizer Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.4.3 Pfizer Inc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pfizer Inc. Main Business Overview
13.4.5 Pfizer Inc. Latest Developments
13.5 ASKA Pharmaceutical Co., Ltd.
13.5.1 ASKA Pharmaceutical Co., Ltd. Company Information
13.5.2 ASKA Pharmaceutical Co., Ltd. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.5.3 ASKA Pharmaceutical Co., Ltd. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 ASKA Pharmaceutical Co., Ltd. Main Business Overview
13.5.5 ASKA Pharmaceutical Co., Ltd. Latest Developments
13.6 Bausch Health
13.6.1 Bausch Health Company Information
13.6.2 Bausch Health Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.6.3 Bausch Health Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bausch Health Main Business Overview
13.6.5 Bausch Health Latest Developments
13.7 Johnson & Johnson Services, Inc.
13.7.1 Johnson & Johnson Services, Inc. Company Information
13.7.2 Johnson & Johnson Services, Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.7.3 Johnson & Johnson Services, Inc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Johnson & Johnson Services, Inc. Main Business Overview
13.7.5 Johnson & Johnson Services, Inc. Latest Developments
13.8 Janssen Global Services
13.8.1 Janssen Global Services Company Information
13.8.2 Janssen Global Services Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.8.3 Janssen Global Services Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Janssen Global Services Main Business Overview
13.8.5 Janssen Global Services Latest Developments
13.9 Takeda Pharmaceutical Company Limited
13.9.1 Takeda Pharmaceutical Company Limited Company Information
13.9.2 Takeda Pharmaceutical Company Limited Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.9.3 Takeda Pharmaceutical Company Limited Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.9.5 Takeda Pharmaceutical Company Limited Latest Developments
13.10 Merck & Co., Inc.
13.10.1 Merck & Co., Inc. Company Information
13.10.2 Merck & Co., Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.10.3 Merck & Co., Inc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Merck & Co., Inc. Main Business Overview
13.10.5 Merck & Co., Inc. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Hepatic Encephalopathy Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Hepatic Encephalopathy Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Oral
Table 4. Major Players of Injectable
Table 5. Global Hepatic Encephalopathy Treatment Sales by Route (2018-2023) & (K Units)
Table 6. Global Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
Table 7. Global Hepatic Encephalopathy Treatment Revenue by Route (2018-2023) & ($ million)
Table 8. Global Hepatic Encephalopathy Treatment Revenue Market Share by Route (2018-2023)
Table 9. Global Hepatic Encephalopathy Treatment Sale Price by Route (2018-2023) & (US$/Unit)
Table 10. Global Hepatic Encephalopathy Treatment Sales by Application (2018-2023) & (K Units)
Table 11. Global Hepatic Encephalopathy Treatment Sales Market Share by Application (2018-2023)
Table 12. Global Hepatic Encephalopathy Treatment Revenue by Application (2018-2023)
Table 13. Global Hepatic Encephalopathy Treatment Revenue Market Share by Application (2018-2023)
Table 14. Global Hepatic Encephalopathy Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Hepatic Encephalopathy Treatment Sales by Company (2018-2023) & (K Units)
Table 16. Global Hepatic Encephalopathy Treatment Sales Market Share by Company (2018-2023)
Table 17. Global Hepatic Encephalopathy Treatment Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Hepatic Encephalopathy Treatment Revenue Market Share by Company (2018-2023)
Table 19. Global Hepatic Encephalopathy Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Hepatic Encephalopathy Treatment Producing Area Distribution and Sales Area
Table 21. Players Hepatic Encephalopathy Treatment Products Offered
Table 22. Hepatic Encephalopathy Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Hepatic Encephalopathy Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Hepatic Encephalopathy Treatment Sales Market Share Geographic Region (2018-2023)
Table 27. Global Hepatic Encephalopathy Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Hepatic Encephalopathy Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Hepatic Encephalopathy Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Hepatic Encephalopathy Treatment Sales Market Share by Country/Region (2018-2023)
Table 31. Global Hepatic Encephalopathy Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Hepatic Encephalopathy Treatment Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Hepatic Encephalopathy Treatment Sales by Country (2018-2023) & (K Units)
Table 34. Americas Hepatic Encephalopathy Treatment Sales Market Share by Country (2018-2023)
Table 35. Americas Hepatic Encephalopathy Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Hepatic Encephalopathy Treatment Revenue Market Share by Country (2018-2023)
Table 37. Americas Hepatic Encephalopathy Treatment Sales by Type (2018-2023) & (K Units)
Table 38. Americas Hepatic Encephalopathy Treatment Sales by Application (2018-2023) & (K Units)
Table 39. APAC Hepatic Encephalopathy Treatment Sales by Region (2018-2023) & (K Units)
Table 40. APAC Hepatic Encephalopathy Treatment Sales Market Share by Region (2018-2023)
Table 41. APAC Hepatic Encephalopathy Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Hepatic Encephalopathy Treatment Revenue Market Share by Region (2018-2023)
Table 43. APAC Hepatic Encephalopathy Treatment Sales by Route (2018-2023) & (K Units)
Table 44. APAC Hepatic Encephalopathy Treatment Sales by Application (2018-2023) & (K Units)
Table 45. Europe Hepatic Encephalopathy Treatment Sales by Country (2018-2023) & (K Units)
Table 46. Europe Hepatic Encephalopathy Treatment Sales Market Share by Country (2018-2023)
Table 47. Europe Hepatic Encephalopathy Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Hepatic Encephalopathy Treatment Revenue Market Share by Country (2018-2023)
Table 49. Europe Hepatic Encephalopathy Treatment Sales by Type (2018-2023) & (K Units)
Table 50. Europe Hepatic Encephalopathy Treatment Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Hepatic Encephalopathy Treatment Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Hepatic Encephalopathy Treatment Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Hepatic Encephalopathy Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Hepatic Encephalopathy Treatment Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Hepatic Encephalopathy Treatment Sales by Route (2018-2023) & (K Units)
Table 56. Middle East & Africa Hepatic Encephalopathy Treatment Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Hepatic Encephalopathy Treatment
Table 58. Key Market Challenges & Risks of Hepatic Encephalopathy Treatment
Table 59. Key Industry Trends of Hepatic Encephalopathy Treatment
Table 60. Hepatic Encephalopathy Treatment Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Hepatic Encephalopathy Treatment Distributors List
Table 63. Hepatic Encephalopathy Treatment Customer List
Table 64. Global Hepatic Encephalopathy Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Hepatic Encephalopathy Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Hepatic Encephalopathy Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Hepatic Encephalopathy Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Hepatic Encephalopathy Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Hepatic Encephalopathy Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Hepatic Encephalopathy Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Hepatic Encephalopathy Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Hepatic Encephalopathy Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Hepatic Encephalopathy Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Hepatic Encephalopathy Treatment Sales Forecast by Route (2024-2029) & (K Units)
Table 75. Global Hepatic Encephalopathy Treatment Revenue Forecast by Route (2024-2029) & ($ Millions)
Table 76. Global Hepatic Encephalopathy Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Hepatic Encephalopathy Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Mallinckrodt Pharmaceuticals Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 79. Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 80. Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Mallinckrodt Pharmaceuticals Main Business
Table 82. Mallinckrodt Pharmaceuticals Latest Developments
Table 83. Salix Pharmaceuticals Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 84. Salix Pharmaceuticals Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 85. Salix Pharmaceuticals Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Salix Pharmaceuticals Main Business
Table 87. Salix Pharmaceuticals Latest Developments
Table 88. GlaxoSmithKline plc. Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 89. GlaxoSmithKline plc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 90. GlaxoSmithKline plc. Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. GlaxoSmithKline plc. Main Business
Table 92. GlaxoSmithKline plc. Latest Developments
Table 93. Pfizer Inc. Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 95. Pfizer Inc. Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Pfizer Inc. Main Business
Table 97. Pfizer Inc. Latest Developments
Table 98. ASKA Pharmaceutical Co., Ltd. Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 99. ASKA Pharmaceutical Co., Ltd. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 100. ASKA Pharmaceutical Co., Ltd. Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. ASKA Pharmaceutical Co., Ltd. Main Business
Table 102. ASKA Pharmaceutical Co., Ltd. Latest Developments
Table 103. Bausch Health Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 104. Bausch Health Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 105. Bausch Health Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Bausch Health Main Business
Table 107. Bausch Health Latest Developments
Table 108. Johnson & Johnson Services, Inc. Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 109. Johnson & Johnson Services, Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 110. Johnson & Johnson Services, Inc. Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Johnson & Johnson Services, Inc. Main Business
Table 112. Johnson & Johnson Services, Inc. Latest Developments
Table 113. Janssen Global Services Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 114. Janssen Global Services Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 115. Janssen Global Services Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Janssen Global Services Main Business
Table 117. Janssen Global Services Latest Developments
Table 118. Takeda Pharmaceutical Company Limited Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 119. Takeda Pharmaceutical Company Limited Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 120. Takeda Pharmaceutical Company Limited Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Takeda Pharmaceutical Company Limited Main Business
Table 122. Takeda Pharmaceutical Company Limited Latest Developments
Table 123. Merck & Co., Inc. Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck & Co., Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 125. Merck & Co., Inc. Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Merck & Co., Inc. Main Business
Table 127. Merck & Co., Inc. Latest Developments
List of Figures
Figure 1. Picture of Hepatic Encephalopathy Treatment
Figure 2. Hepatic Encephalopathy Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Hepatic Encephalopathy Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Hepatic Encephalopathy Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Hepatic Encephalopathy Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Oral
Figure 10. Product Picture of Injectable
Figure 11. Global Hepatic Encephalopathy Treatment Sales Market Share by Route in 2022
Figure 12. Global Hepatic Encephalopathy Treatment Revenue Market Share by Route (2018-2023)
Figure 13. Hepatic Encephalopathy Treatment Consumed in Hospital Pharmacy
Figure 14. Global Hepatic Encephalopathy Treatment Market: Hospital Pharmacy (2018-2023) & (K Units)
Figure 15. Hepatic Encephalopathy Treatment Consumed in Retail Pharmacy
Figure 16. Global Hepatic Encephalopathy Treatment Market: Retail Pharmacy (2018-2023) & (K Units)
Figure 17. Hepatic Encephalopathy Treatment Consumed in Online Pharmacy
Figure 18. Global Hepatic Encephalopathy Treatment Market: Online Pharmacy (2018-2023) & (K Units)
Figure 19. Global Hepatic Encephalopathy Treatment Sales Market Share by Application (2022)
Figure 20. Global Hepatic Encephalopathy Treatment Revenue Market Share by Application in 2022
Figure 21. Hepatic Encephalopathy Treatment Sales Market by Company in 2022 (K Units)
Figure 22. Global Hepatic Encephalopathy Treatment Sales Market Share by Company in 2022
Figure 23. Hepatic Encephalopathy Treatment Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Hepatic Encephalopathy Treatment Revenue Market Share by Company in 2022
Figure 25. Global Hepatic Encephalopathy Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Hepatic Encephalopathy Treatment Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Hepatic Encephalopathy Treatment Sales 2018-2023 (K Units)
Figure 28. Americas Hepatic Encephalopathy Treatment Revenue 2018-2023 ($ Millions)
Figure 29. APAC Hepatic Encephalopathy Treatment Sales 2018-2023 (K Units)
Figure 30. APAC Hepatic Encephalopathy Treatment Revenue 2018-2023 ($ Millions)
Figure 31. Europe Hepatic Encephalopathy Treatment Sales 2018-2023 (K Units)
Figure 32. Europe Hepatic Encephalopathy Treatment Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Hepatic Encephalopathy Treatment Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Hepatic Encephalopathy Treatment Revenue 2018-2023 ($ Millions)
Figure 35. Americas Hepatic Encephalopathy Treatment Sales Market Share by Country in 2022
Figure 36. Americas Hepatic Encephalopathy Treatment Revenue Market Share by Country in 2022
Figure 37. Americas Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
Figure 38. Americas Hepatic Encephalopathy Treatment Sales Market Share by Application (2018-2023)
Figure 39. United States Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Hepatic Encephalopathy Treatment Sales Market Share by Region in 2022
Figure 44. APAC Hepatic Encephalopathy Treatment Revenue Market Share by Regions in 2022
Figure 45. APAC Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
Figure 46. APAC Hepatic Encephalopathy Treatment Sales Market Share by Application (2018-2023)
Figure 47. China Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Hepatic Encephalopathy Treatment Sales Market Share by Country in 2022
Figure 55. Europe Hepatic Encephalopathy Treatment Revenue Market Share by Country in 2022
Figure 56. Europe Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
Figure 57. Europe Hepatic Encephalopathy Treatment Sales Market Share by Application (2018-2023)
Figure 58. Germany Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Hepatic Encephalopathy Treatment Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Hepatic Encephalopathy Treatment Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
Figure 66. Middle East & Africa Hepatic Encephalopathy Treatment Sales Market Share by Application (2018-2023)
Figure 67. Egypt Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Hepatic Encephalopathy Treatment in 2022
Figure 73. Manufacturing Process Analysis of Hepatic Encephalopathy Treatment
Figure 74. Industry Chain Structure of Hepatic Encephalopathy Treatment
Figure 75. Channels of Distribution
Figure 76. Global Hepatic Encephalopathy Treatment Sales Market Forecast by Region (2024-2029)
Figure 77. Global Hepatic Encephalopathy Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Hepatic Encephalopathy Treatment Sales Market Share Forecast by Route (2024-2029)
Figure 79. Global Hepatic Encephalopathy Treatment Revenue Market Share Forecast by Route (2024-2029)
Figure 80. Global Hepatic Encephalopathy Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Hepatic Encephalopathy Treatment Revenue Market Share Forecast by Application (2024-2029)


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 肝性脳症治療のグローバル市場予測2023-2029(Global Hepatic Encephalopathy Treatment Market Growth 2023-2029)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆